News | March 09, 2012

First U.S. PAD Patient Enrolled in Forward-Looking OCT Clinical Trial


March 9, 2012 — Avinger Inc. announced the enrollment of the first U.S. patient in the CONNECT II global clinical trial evaluating the safety and efficacy of Ocelot. The device is the first chronic total occlusion (CTO) crossing catheter using forward-looking optical coherence tomography (OCT) to treat patients with peripheral artery disease (PAD).

The first patient was enrolled by Ian Cawich, M.D., of Arkansas Heart Hospital. This announcement comes two weeks after Dr. Bernhard Reimers enrolled the first European patient in the CONNECT II trial at Ospedale di Mirano in Mirano, Italy.

Currently CE marked, Ocelot is designed for crossing completely blocked arteries, or chronic total occlusions (CTOs), in the legs while simultaneously using OCT to navigate inside the arteries.

“We hope that physicians using Ocelot can now help prevent even more leg amputations in people suffering from PAD,” said Avinger founder and CEO John B. Simpson, Ph.D., M.D.

The Ocelot catheter uses OCT technology as a navigation tool with the goal of traversing CTOs more safely and effectively as part of a procedure to restore blood flow back to normal in the legs. It allows physicians, in real time, to see what’s happening inside the arteries during the actual intervention, giving patients a better chance to receive the best treatment possible during a single hospital visit.

“We are participating in CONNECT II because our patient, if treated with other current options on the medical market, could face amputation and death,” said Cawich. “With Avinger’s Ocelot, we believe this patient can be saved right now from both.”

For more information: http://avinger.com


Related Content

News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — A programming algorithm, being tested by HonorHealth Research Institute for those patients with new or ...

Home June 20, 2024
Home
Subscribe Now